ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1226

Preliminary Findings in the Validation of the Modified Pain and Symptom Assessment Tool in Juvenile Fibromyalgia Syndrome

Daniella Schocken1, Mark Connelly2, Sabrina Gmuca3, Andrea Ramirez4, Mary Ellen Riordan5, Tracy Ting6, Susmita Kashikar-Zuck7 and Jennifer Weiss8, 1Children's Mercy Kansas City, Tampa, FL, 2Children’s Mercy Kansas City/University of Missouri-Kansas City School of Medicine, Kansas City, MO, 3Children's Hospital of Philadelphia, Philadelphia, PA, 4Baylor College of Medicine, Houston, TX, 5Hackensack University Medical Center, Hackensack, NJ, 6Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7University of Cincinnati College of Medicine; Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 8Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ

Meeting: ACR Convergence 2025

Keywords: Diagnostic criteria, fibromyalgia, pain, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Diagnosing juvenile fibromyalgia (JFM) in youth with chronic musculoskeletal (MSK) pain is challenging in the absence of a validated diagnostic tool. The Pain and Symptom Assessment Tool (PSAT) was developed from modifications to the ACR criteria for adult FM (2010) to aid in JFM diagnosis. This ongoing study aims to validate the PSAT as a diagnostic tool by demonstrating how measured differences in pain distribution and accompanying symptoms distinguish JFM from other causes of chronic MSK pain such as JIA or more localized painful disorders.

Methods: This multicenter, cross-sectional observational study enrolled English- and Spanish-speaking adolescents (age range: 11 – 17) with MSK pain of ≥3 months’ duration and a clinical diagnosis of JFM, JIA, or localized MSK pain. All participants completed the PSAT, which included both assessment of pain location using the Michigan Body Map© (MBM) and a Symptom Severity Index (SSI) comprised of an inventory of associated symptoms with severity indices for fatigue, nonrestorative sleep, and impaired memory or concentration. One-way ANOVA was performed to look for differences in MBM totals and SSI between diagnostic groups, and post hoc analysis was carried out with Tukey’s HSD test to determine the significance of between-group differences. Yunus and Masi’s criteria for primary JFM (1985), which include ≥5 tender points on physical exam, were used by study staff as a diagnostic standard with which to evaluate all participants for clinical features consistent with JFM.

Results: A total of 158 participants were enrolled across 5 clinical sites. Participant diagnoses and characteristics are detailed in Figure 1. The average pain intensity rating among study participants was 5.7/10 (sd = 2.2), and 77/158 (49%) participants had ≥5 tender points on physical exam. Yunus and Masi’s criteria were fulfilled by 47/60 (78%) participants with a clinical diagnosis of JFM and one participant with JIA. No participants with localized pain met these criteria. MBM totals and SSI both differed between diagnostic groups with F(2, 155) = 43.43 (p < 0.001, 95% CI [0.26, 1.00]) and F(2, 155) = 25.79 (p < 0.001, 95% CI [0.15, 1.00]), respectively. Post hoc analysis revealed significantly higher MBM totals and SSI among participants with JFM when compared to those with either localized MSK pain or JIA (p < 0.001). Figures 2 and 3 illustrate the distribution of MBM totals and SSI across participant diagnoses.

Conclusion: Analysis of these results from PSAT administration to adolescents with chronic MSK pain shows clear differences in measured pain distribution and symptom severity between those participants diagnosed clinically with JFM and those with other chronically painful MSK conditions. As recruitment for this study is ongoing, sensitivity and specificity of the PSAT in comparison with Yunus and Masi’s criteria for the diagnosis of JFM will be determined following completion of further data collection and analysis. However, these preliminary results support the utility of the PSAT in distinguishing JFM from other causes of chronic MSK pain in pediatric patients, highlighting a valuable tool to improve the consistency of case definitions in research and ease diagnostic uncertainty in clinical care.

Supporting image 1Figure 1: A table providing demographic and clinical characteristics of enrolled participants broken down by diagnosis. Included are age, gender, race, ethnicity, language of study completion, pain intensity, MBM total, SSI, tender point exam findings, and fulfillment of Yunus and Masi’s critera.

Supporting image 2Figure 2: A box plot of total painful locations on Michigan Body Map (MBM) broken down by participant diagnosis. Center bars represent the median. Upper and lower limits of boxes are interquartile ranges. The limits of the whiskers are the full range with significant outliers excluded and plotted separately.

Supporting image 3Figure 3: A box plot of participants’ Symptom Severity Index (SSI) broken down by diagnosis. Center bars represent the median. Upper and lower limits of boxes are interquartile ranges. The limits of the whiskers are the full range.


Disclosures: D. Schocken: None; M. Connelly: None; S. Gmuca: None; A. Ramirez: None; M. Riordan: None; T. Ting: None; S. Kashikar-Zuck: None; J. Weiss: None.

To cite this abstract in AMA style:

Schocken D, Connelly M, Gmuca S, Ramirez A, Riordan M, Ting T, Kashikar-Zuck S, Weiss J. Preliminary Findings in the Validation of the Modified Pain and Symptom Assessment Tool in Juvenile Fibromyalgia Syndrome [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/preliminary-findings-in-the-validation-of-the-modified-pain-and-symptom-assessment-tool-in-juvenile-fibromyalgia-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/preliminary-findings-in-the-validation-of-the-modified-pain-and-symptom-assessment-tool-in-juvenile-fibromyalgia-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology